238 related articles for article (PubMed ID: 10085276)
21. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
Martinez-Rebollar M; Lonca M; Perez I; Soy D; Brunet M; Martin R; Coll O; Hernandez S; Laguno M; Milinkovic A; Larrousse M; Calvo M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2011 Dec; 33(6):772-7. PubMed ID: 22105596
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.
Acosta EP; Bardeguez A; Zorrilla CD; Van Dyke R; Hughes MD; Huang S; Pompeo L; Stek AM; Pitt J; Watts DH; Smith E; Jiménez E; Mofenson L;
Antimicrob Agents Chemother; 2004 Feb; 48(2):430-6. PubMed ID: 14742191
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
[TBL] [Abstract][Full Text] [Related]
26. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
Buss N; Snell P; Bock J; Hsu A; Jorga K
Br J Clin Pharmacol; 2001 Sep; 52(3):255-64. PubMed ID: 11560557
[TBL] [Abstract][Full Text] [Related]
27. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
[TBL] [Abstract][Full Text] [Related]
28. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
[TBL] [Abstract][Full Text] [Related]
29. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
30. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
31. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
32. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
[TBL] [Abstract][Full Text] [Related]
33. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
Merry C; Barry MG; Mulcahy F; Ryan M; Heavey J; Tjia JF; Gibbons SE; Breckenridge AM; Back DJ
AIDS; 1997 Mar; 11(4):F29-33. PubMed ID: 9084785
[TBL] [Abstract][Full Text] [Related]
34. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.
Kilby JM; Hill A; Buss N
HIV Med; 2002 Apr; 3(2):97-104. PubMed ID: 12010356
[TBL] [Abstract][Full Text] [Related]
35. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Ford SL; Reddy YS; Anderson MT; Murray SC; Fernandez P; Stein DS; Johnson MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2201-6. PubMed ID: 16723584
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
37. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
Reddy YS; Ford SL; Anderson MT; Murray SC; Ng-Cashin J; Johnson MA
Antimicrob Agents Chemother; 2007 Apr; 51(4):1202-8. PubMed ID: 17261626
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Autar RS; Ananworanich J; Apateerapong W; Sankote J; Hill A; Hirschel B; Cooper D; Lange J; Phanuphak P; Ruxrungtham K; Burger D
J Antimicrob Chemother; 2004 Oct; 54(4):785-90. PubMed ID: 15329366
[TBL] [Abstract][Full Text] [Related]
40. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
